MRK Valuation Metrics
MRK Stock Price Metrics
MRK Dividend Metrics
MRK Growth Rate Metrics
MRK Discounted Cash Flow Metrics
| Fair Value Price | $213.59 |
| Margin of Safety | 78.58% |
MRK Revenue Metrics
MRK PE Ratio Metrics
| PE Ratio | 33.69 |
| PE Ratio Avg TTM | 15.70 |
| PE Ratio Avg 3Y | 94.44 |
| Current VS TTM Avg | +114.56% |
| Current VS 3Y Avg | -64.33% |
| Current VS 5Y Avg | -48.41% |
MRK PS Ratio Metrics
| PS Ratio | 4.51 |
| PS Ratio Avg TTM | 3.87 |
| PS Ratio Avg 3Y | 4.31 |
| Current VS TTM Avg | +16.66% |
| Current VS 3Y Avg | +4.74% |
| Current VS 5Y Avg | +3.92% |
MRK PB Ratio Metrics
| PB Ratio | 6.44 |
| PB Ratio Avg TTM | 4.97 |
| PB Ratio Avg 3Y | 6.03 |
| Current VS TTM Avg | +29.69% |
| Current VS 3Y Avg | +6.80% |
| Current VS 5Y Avg | +7.80% |
MRK Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 20.95 |
| PFCF Ratio Avg TTM | 18.10 |
| PFCF Ratio Avg 3Y | 21.02 |
| Current VS TTM Avg | +15.76% |
| Current VS 3Y Avg | -0.35% |
| Current VS 5Y Avg | -3.01% |
MRK Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.96 |
| Debt/Equity Ratio Avg TTM | 0.90 |
| Debt/Equity Ratio Avg 3Y | 0.86 |
| Current VS TTM Avg | +7.26% |
| Current VS 3Y Avg | +10.98% |
| Current VS 5Y Avg | +1.23% |
MRK PEG Ratio Metrics
| PEG Ratio | 1.81 |
| PEG Ratio Avg TTM | 1.81 |
| PEG Ratio Avg 3Y | 1.81 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
MRK FCF Yield
| FCF Yield | 4.77% |
| FCF Yield Avg TTM | 5.86% |
| FCF Yield Avg 3Y | 5.24% |
| Current VS TTM Avg | -18.65% |
| Current VS 3Y Avg | -8.89% |
| Current VS 5Y Avg | -5.36% |
MRK Earnings Yield
| Earnings Yield | 2.97% |
| Earnings Yield Avg TTM | 6.92% |
| Earnings Yield Avg 3Y | 4.57% |
| Current VS TTM Avg | -57.11% |
| Current VS 3Y Avg | -34.98% |
| Current VS 5Y Avg | -37.56% |
MRK EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 18.76 |
| Ev/Ebit Ratio Avg TTM | 12.18 |
| Ev/Ebit Ratio Avg 3Y | 31.17 |
| Current VS TTM Avg | +54.02% |
| Current VS 3Y Avg | -39.81% |
| Current VS 5Y Avg | -32.69% |
MRK EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 14.96 |
| Ev/Ebitda Ratio Avg TTM | 9.96 |
| Ev/Ebitda Ratio Avg 3Y | 19.29 |
| Current VS TTM Avg | +50.16% |
| Current VS 3Y Avg | -22.46% |
| Current VS 5Y Avg | -15.92% |
MRK EV/Assets Ratio Metrics
| Ev/Assets Ratio | 2.64 |
| Ev/Assets Ratio Avg TTM | 2.21 |
| Ev/Assets Ratio Avg 3Y | 2.57 |
| Current VS TTM Avg | +19.62% |
| Current VS 3Y Avg | +2.53% |
| Current VS 5Y Avg | +4.29% |
MRK EV/Sales Ratio Metrics
| Ev/Sales Ratio | 5.17 |
| Ev/Sales Ratio Avg TTM | 4.32 |
| Ev/Sales Ratio Avg 3Y | 4.75 |
| Current VS TTM Avg | +19.65% |
| Current VS 3Y Avg | +8.87% |
| Current VS 5Y Avg | +8.49% |
MRK Current Ratio Metrics
| Current Ratio | 1.54 |
| Current Ratio Avg TTM | 1.45 |
| Current Ratio Avg 3Y | 1.41 |
| Current VS TTM Avg | +6.21% |
| Current VS 3Y Avg | +9.61% |
| Current VS 5Y Avg | +16.81% |
MRK Quick Ratio Metrics
| Quick Ratio | 1.30 |
| Quick Ratio Avg TTM | 1.23 |
| Quick Ratio Avg 3Y | 1.17 |
| Current VS TTM Avg | +6.12% |
| Current VS 3Y Avg | +11.11% |
| Current VS 5Y Avg | +19.82% |
MRK ROIC Metrics
| ROIC | 18.27% |
| ROIC Avg 3Y | 14.12% |
| ROIC Avg 5Y | 12.73% |
| Current VS 3Y Avg | +29.39% |
| Current VS 5Y Avg | +43.46% |
| Current VS 10Y Avg | +79.07% |
MRK Return on Assets Metrics
| ROA | 13.34 |
| ROA Avg TTM | 13.98 |
| ROA Avg 3Y | 10.40 |
| Current VS TTM Avg | -4.58% |
| Current VS 3Y Avg | +28.27% |
| Current VS 5Y Avg | +29.79% |
MRK Return on Equity Metrics
| ROE | 34.70 |
| ROE Avg TTM | 35.83 |
| ROE Avg 3Y | 26.05 |
| Current VS TTM Avg | -3.15% |
| Current VS 3Y Avg | +33.21% |
| Current VS 5Y Avg | +25.21% |
MRK Net Profit Margin Metrics
| Net Profit Margin | 28.12% |
| Net Profit Margin Avg TTM | 27.40% |
| Net Profit Margin Avg 3Y | 19.98% |
| Current VS TTM Avg | +2.63% |
| Current VS 3Y Avg | +40.78% |
| Current VS 5Y Avg | +36.38% |
Last Updated: Tuesday, June 9, 2026
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis